看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
; C2 X3 i6 N7 H8 J# n7 U% k* v' D6 W8 ?3 F8 d* v2 A3 o/ G
* T7 F; `5 J: j2 ?7 [Currently available feasibility data for possible combination strategies. # }. q9 V& d0 |: y( h6 B
————————————————————————————————2 [) V! M7 b: H
Combination Feasibility according to preliminary data
0 p$ g) r5 c: |* P6 x5 t S) Q( o——————————————————————————————————
' O% w, {2 q" d$ j( }4 u2 P! |6 _Bevacizumab + sorafenib Yes, reduced dose
1 x( _5 Q+ S) n0 d+ TBevacizumab + sunitinib† No ' y/ F6 Y/ h1 p: _( j, Z0 v. q) c7 u
Bevacizumab + temsirolimus Yes - N; d9 ]' q3 y# @. h6 }
Bevacizumab + everolimus Yes 2 c# B8 S) ]2 D1 u6 s5 s1 v
Sorafenib + sunitinib ? 7 U/ d* i/ ^3 P
Sorafenib + temsirolimus Yes, reduced dose 3 K# T9 m( Z0 K. z
Sorafenib + everolimus Yes, reduced dose
6 W$ z: q/ i/ |* LSunitinib + temsirolimus† No ' i9 C/ D, [. a4 N, S, `' y
Sunitinib + everolimus ? % [/ d3 H6 b# @& [
Temsirolimus + everolimus ?
0 l- e Y7 z% Z1 @& A% T4 k( }) b: Z7 A————————————————————
8 S$ N; ^: o7 P* z5 N+ p: y: J2 @†Led to US FDA warning.
c5 |+ ?' N+ {" W( C" ^?: As yet unattempted combination." D7 B0 e" D9 R) t- l8 B5 i# `# u
|
显身卡
" T- m2 ]5 ]& y g0 M- C7 s! y0 A3 A
